Nosiheptide CAS 56377-79-8

Nosiheptide More Info

Nosiheptide is a sulfur-rich, thiopeptide class of antibiotic produced by the bacterium Streptomyces actuosus, with the CAS Registry Number 56377-79-8. Its complex molecular architecture is characterized by a macrocyclic framework incorporating multiple modified amino acids, thiazole rings, and a unique  moiety, all stabilized by a central peptide backbone. This intricate, rigid structure is essential for its potent biological activity and stability. It typically presents as a yellowish-brown powder, reflecting its highly conjugated system.

The antibiotic exerts its potent bactericidal effect through a highly specific mechanism: the inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit. Unlike macrolides or lincosamides, nosiheptide interacts with a distinct site on the 23S ribosomal RNA, near the GTPase-associated center. This binding directly interferes with the function of elongation factor G, thereby blocking the translocation step of the growing peptide chain and stalling the entire translation process, which is lethal to susceptible bacteria.

Nosiheptide exhibits a narrow but potent spectrum of activity, primarily against Gram-positive bacteria. It is highly effective against major veterinary pathogens such as Clostridium and Staphylococcus species. Consequently, its primary historical and commercial application has been as a growth promoter and therapeutic agent in animal husbandry, particularly in poultry and swine, to improve feed efficiency and prevent or treat enteric infections. Its use in human medicine has been extremely limited due to its physicochemical properties and the development of other drug classes.

This compound is extremely insoluble in water and most common organic solvents, a property that confines its use almost exclusively to oral administration in animal feed. It is not absorbed from the gastrointestinal tract, which is a key safety feature for its use as a feed additive, as it acts locally within the gut lumen without systemic exposure. Formulations are designed as premixes to be uniformly blended into feed. Its stability in feed and resistance to degradation in the digestive tract are critical for its efficacy.

The safety profile of nosiheptide in its target animals is favorable, largely due to its lack of systemic absorption. This results in no detectable residues in meat, milk, or eggs, making it a compound of choice where residue avoidance is paramount. However, due to global concerns about antimicrobial resistance linked to the use of antibiotics as growth promoters, its use for this purpose has been banned or severely restricted in many regions, including the European Union. Its current role is more focused on specific therapeutic veterinary applications under veterinary prescription, and it remains a fascinating molecule for studying ribosomal function and thiopeptide chemistry.